Renin and Renal Biomarker Response to Angiotensin II
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Septic shock continues to exert a large economic burden around the world. Several
developments have occurred that lead to the current study. First, angiotensin II is the
newest FDA approved vasopressor agent indicated for use in vasodilatory shock. Several
subgroups from the approval trial have indicated that angiotensin II may confer a survival
benefit in certain conditions, including those patients requiring continuous renal
replacement therapy, those with altered angiotensin I: angiotensin II ratios, and most
recently, those with elevated renin levels (which may serve as a surrogate for dysfunctional
angiotensin 1: angiotensin II ratios). This open-label, sequential period pilot study will
evaluate angiotensin II and biomarker response (renin) in the treatment of septic shock.